Detalles de la búsqueda
1.
Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial.
BMC Neurol
; 21(1): 126, 2021 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33740902
2.
Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials.
J Headache Pain
; 22(1): 16, 2021 Mar 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-33781209
3.
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1).
Cephalalgia
; 40(3): 241-254, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32075406
4.
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study.
J Headache Pain
; 21(1): 120, 2020 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33023473
5.
Correction to: Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials.
J Headache Pain
; 22(1): 46, 2021 May 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-34034644
6.
Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine.
Front Immunol
; 12: 765822, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34759933
7.
Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients.
Endocrinol Diabetes Metab
; 4(2): e00217, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33855218
8.
Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study.
Clin Ther
; 42(12): 2254-2265.e3, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33250209
9.
Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine.
Pharmacol Res Perspect
; 8(2): e00567, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32155317
10.
Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.
Neurology
; 94(13): e1365-e1377, 2020 03 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-32209650
11.
Corrigendum to "Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study" [Clin Therapeut 42 (12) (2020) 2254-2265].
Clin Ther
; 43(4): 791, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33814199
Resultados
1 -
11
de 11
1
Próxima >
>>